Quotes 5-day view Delayed Nasdaq
01/27/2023
01/30/2023
01/31/2023
02/01/2023
02/02/2023
Date
53.09(c)
51.81(c)
53.41(c)
52.69(c)
54.335
Last
933 779
986 014
1 115 555
1 585 624
394 307
Volume
+3.98%
-2.41%
+3.09%
-1.35%
+3.12%
Change
Estimated financial data (e) (USD)
Sales 2022
14,3 M
-
-
Net income 2022
-752 M
-
-
Net cash position 2022
1 110 M
-
-
P/E ratio 2022
-3,93x
Yield 2022
-
Sales 2023
74,0 M
-
-
Net income 2023
-798 M
-
-
Net cash position 2023
423 M
-
-
P/E ratio 2023
-3,85x
Yield 2023
-
Capitalization
3 034 M
3 034 M
-
EV / Sales 2022
134x
EV / Sales 2023
35,3x
Nbr of Employees
-
Free-Float
94,1%
Mirati Therapeutics Inc is a United States-based clinical-stage biotechnology company that is focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. The Company is using its scientific expertise to develop novel solutions in two registration-enabling programs:...
Ratings of Mirati Therapeutics, Inc.
All news about MIRATI THERAPEUTICS, INC.
News in other languages on MIRATI THERAPEUTICS, INC.
Analyst Recommendations on MIRATI THERAPEUTICS, INC.
ETFs positioned on MIRATI THERAPEUTICS, INC. ETFs and Trackers with Trackinsight
Amgen says Lumakras cuts risk of lung cancer progression by 34%
Chart MIRATI THERAPEUTICS, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends MIRATI THERAPEUTICS, INC.
Short Term Mid-Term Long Term Trends Bullish Bearish Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
52,69 $
Average target price
71,27 $
Spread / Average Target
35,3%
Please enable JavaScript in your browser's settings to use dynamic charts.